Study of zanidatamab plus tucatinib and chemo for HER2+ advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing a combination of two targeted drugs (zanidatamab and tucatinib) plus chemotherapy for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It's for those who have already had at least one other anti-HER2 treatment but no more than three.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your breast cancer must be HER2-positive (confirmed by a lab test) and cannot be removed by surgery or has spread to other parts of the body.
- You must have had at least 1 but no more than 3 previous treatments for advanced disease that included a HER2-targeted therapy.
- You need to be in fairly good health (able to care for yourself but not necessarily active) and have adequate organ function (kidney, liver, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.
This trial tests a combination of three drugs (a targeted therapy called chidamide, an immunotherapy called a PD-1 inhibitor, and a drug called anlotinib that blocks blood vessel growth) for people with HER2-low, hormone receptor-positive breast cancer that has spread to other parts of the body or cannot be removed with surgery. It is for those whose cancer has stopped responding to hormone therapy and who have had little or no prior chemotherapy.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.